(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 January 2023 (26.01.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/003815 A1

(51) International Patent Classification:
A61P 27/02 (2006.01) *C07K 14/71* (2006.01)

(21) International Application Number:
PCT/US2022/037479

(22) International Filing Date:
18 July 2022 (18.07.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/223,265 19 July 2021 (19.07.2021) US

(71) Applicant: **ACCELERON PHARMA INC.** [US/US]; 128 Sidney Street, Cambridge, MA 02139 (US).

(72) Inventor: **DE OLIVEIRA PENA, Janethe**; c/o Acceleron Pharma, Inc., 128 Sidney Street, Cambridge, MA 02139 (US).

(74) Agent: **VARMA, Anita** et al.; White & Case LLP, 75 State Street, Boston, MA 02109 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: ACTRII PROTEINS AND USES THEREOF



FIG.1

(57) Abstract: In some aspects, the disclosure relates to compositions and methods for decreasing a risk of telangiectasia in a patient receiving a therapeutically effective amount of an ActRII polypeptide, particularly a dosing regimen that decreases the risk of telangiectasia in a patient receiving a therapeutically effective amount of an ActRII polypeptide.

WO 2023/003815 A1